Indeed, targeting CDK12 activity itself or the glycolytic/SGOC metabolism using molecular genetics or pharmacological approaches led to profound attenuation, or even complete reversion, of CDK12-dependent tumor phenotypes in vitro, and severely curbed tumorigenicity and metastatic spreading in vivo. This evidence concerns the gene CDK12 and neoplasm.